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ABSTRACT 
Bacteriophages, having a variety of function in different disciplines, are viruses that invade bacterial cells. Phages are enormously 
essential to the ecology and evolution of bacteria, and have huge impacts on global weather patterns. Due to their easiness to 
manipulate, they have been used in dissimilar types of genetic analysis and also implemented in hydrological tracing. Modified 
filamentous bacteriophages can be used in the production of nanodevices and as an agent in extraction of triacylglycerols. While 
their invention over a decade, they have been subjugated mainly to treat infections caused by bacteria. Phage therapy could 
become a welcome option in this era with a paucity of new antibiotic to battle against multi-drug resistant pathogens. This enemy 
of bacteria can also be used to combat antimicrobial resistance. This annotation is tried to touch the current progress in 
bacteriophage research and applications including biocontrols, diagnostic purposes, drug innovation and new drug delivery 
systems. Regarding efforts made in Ethiopia, there is limited study on isolation of phage and their therapeutic potential. Antibiotic 
resistance is of major community health concern in Ethiopia. Hence, the idea of using bacteriophage should be taken into 
consideration and health professionals should have to show inclination towards phage therapy. Moreover, substantial academic 
efforts have to be made before approval of phage utilization in Ethiopia. 
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INTRODUCTION 
Bacteriophages are bacterial viruses that assault bacterial 
cells and also disrupt bacterial metabolism and cause lysis 
or death of the bacteria1. This review provides 
introductory concepts and some contemporary advances 
concerning bacteriophage. It also gives detail on the 
extensive range of pharmaceutical applications of phages 
including diagnosis of diseases, its prevention and 
treatment. As an intracellular organism, they are found 
everywhere where their bacterial host is present. These 
microscopic parasites are the most ever-present in nature 
and play a major role in maintaining microbial balance on 
this planet2. Bacteriophages (phages) can easily be 
isolated or obtained from their natural foundation such as 
water, soil, sewage, fermented product and unprocessed 
vegetables following standard procedure3. More than 
6000 different phages have been discovered and 
described morphologically4. However, fewer than 1,500 
complete phage genomes were listed in GenBank, many of 
which have not been studied experimentally5.  
Bacteriophages must infect a host bacterial cell with the 
appropriate receptors in the outer membrane in order to 
replicate themselves6. The steps that form the course of 
infection are collectively known as phage life cycle: lytic, 
lysogenic, pseudo-lysogenic, and chronic infection. Some 
of them can only reproduce through a lytic life cycle, in 
which they rupture and slay their host cells (figure 1a). 
Others can alternate between a lytic and lysogenic life 
cycle as shown in figure 1b, in which they do not destroy 
the host cell instead copied along with the host DNA as the 
cell divides7. 
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Figure1a: Lytic cycle of bacteriophage7 
 
Figure1b: Lysogenic cycle of bacteriophage7 
 
Contemporary Advances and Novel Applications 
Bacteriophages are tremendously important to 
the ecosystem and evolution of bacteria8. As one of viruses 
that literally prey on bacteria, phage fills a rapacious role 
in their native ecology. Predators help keep prey 
populations in check, in turn preventing exhaustion of 
available resources9. They are the most copious virus in 
the ocean. A group of phage which is called as 
pelagiphages infects and destroys SAR11 bacteria that 
change dissolved carbon molecules into carbon dioxide 
and influence the quantity of available atmospheric 
carbon. Hence, phages have enormous impacts on the 
global carbon cycle10. It is estimated that bacteriophages 
lyse and eradicate between 15 and 40% of the ocean’s 
bacteria every day, thereby influencing the ratio of 
particulate to dissolved carbon, rates of phytoplankton 
productivity and oxygen production, and perhaps even 
global weather patterns5, 11.  
Recently, Jennifer Brum9 hypothesized that the recycling 
of micronutrients and components of cells such as amino 
acids and nucleic acids has been linked to bacterial lysis 
by phage(s). This likely form a clogged loop in nearly all 
environments where actively growing bacteria use 
resources scavenged from the deceased. The aggregation 
of lysed cells, however, may result in large particles that 
sink in the ocean, contributing to the presence of core 
protein clusters in aphotic zones. This same 
sedimentation carries the organic matter away from 
microbes in the photic zones hence, forcing increased use 
of atmospheric carbon dioxide to generate more biomass9. 
The release of phage induced lysis products changes 
organic carbon from particulate to dissolved forms, which 
makes organic carbon more bio-available and thus acts as 
a catalyst of geochemical nutrient cycles12.  
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Besides their role in the ecological unit, phages can be 
used in a range of genetic analysis and they were the key 
to the development of genetic engineering8,13. Phages are 
thought to extensively contribute to horizontal gene 
transfer in natural surroundings, predominantly 
through transduction14. Of course, they are helpful in the 
genetic and metabolic diversity of their prey 
by transduction and modification of biochemistry during 
the infection process, respectively9. 
Phages are also implemented in hydrological tracing plus 
modeling in river systems, particularly at a place where 
groundwater and surface water interacts15.  They fulfill 
various requirements of the ideal indicators of pathogenic 
contamination. These features contribute to the 
usefulness of phages as surrogates for the fate and 
transport of microbial pathogens of health concern in 
source and drinking waters, with particular reference to: 
(a) indicating the existence of enteric viruses in natural 
waters, (b) contributing to microbial source tracking, (c) 
evaluating the effectiveness of water treatment processes, 
and (d) elucidating the mechanisms involved in the fate 
and transport of enteric viruses in natural or engineered 
filtration media6.  
Genetic modifications of filamentous phages enable us to 
use bacteriophages in the development of material to 
construct films and nanowires in favor of semiconductor 
applications, piezoelectric energy production, and photo-
responsive behaviours16, 17, 18. These materials are also 
being used to make devices like ion batteries and 
catalysts, and to let guided cell growth for human tissue 
formation19, 20, 21. Bacteriophage RNA polymerase as well 
as ribonuclease H has been used to form in vitro genetic 
circuits that have potential future appliance in 
nanodevices and regulation of processes inside artificial 
cells22. These enzymes are also used to make novel 
apparatus for bacterial genome editing and accelerated 
evolution23, 24. Phage Toil has a potential to be a new tool 
for the development of cost effective and bio-friendly 
methods for extraction of triacylglycerols from oleaginous 
bacterium Rhodococcus opacus. Additionally, Phage Toil 
can be a new model phage to advance knowledge 
regarding phage infection mechanisms in Rhodococcus 
and other mycolic acid-containing bacteria25. 
Pharmaceutical Applications 
After discovery in 1915 by Twort26, phages were initially 
used to manage bacterial infections, even if there was no 
widespread acceptance owing to lack of understanding of 
its biology as well as the development of antibiotic in 
1940s. For instance, they have been used as a treatment 
against pathogens such as Shigella dysenteriae as early as 
19192.  
Notwithstanding the call for the discovery of novel 
antibiotics in the European Union and in the United States, 
there is shortage of innovative antibiotics in the 
developmental pipeline. Hence, the re-deployment of 
phage treatment could become an amenable option to 
antimicrobial drugs in this period of progressive spread of 
multi-drug resistant (MDR) and biofilm forming bacterial 
pathogens with a dearth of latest antibiotic to combat 
these microbes2. Lytic phages are alike to antibiotics in 
that they have remarkable antibacterial activity. However, 
therapeutic phages have some at least theoretical merits 
over antibiotics27. 
Bacteriophages have been reported to be more effective 
than antibiotics in treating certain infections28, 29, 30. They 
are ecological friendly and are isolated and identified 
based on natural selection on bacteria in a very rapid 
process compared to new antibiotic development, which 
may take several years that cost millions of dollars for 
clinical trials31. Production of bacteriophage is simple 
unlike the complex and expensive production of antibiotic. 
The initial dose of phage therapy increases exponentially 
if the susceptible bacterial host is available. In such cases, 
there is no need to administer the phages repeatedly, 
however; a repeated dose of antibiotic is required to cure 
the bacterial disease32. No side effects have been reported 
during or after phage application27, but intestinal 
disorders, allergies sometimes even fatal anaphylactic 
reaction and secondary infections are some of the side 
effects of antibiotics33.  
Target range is also one of the main differences between 
phages and antibiotics. Phages are very specific and they 
will normally only lyse strains of one species or a subset of 
strains within a species, it allow targeting of specific 
microbes without disrupting desirable bacterial flora27, 34. 
Bacteriophages duplicate at the site of infection where 
they are mostly desired, but antibiotics travel throughout 
the body and do not concentrate at the site of infection27, 
35, 36. Phages are self replicating as well as self-limiting. 
These living drugs are quickly flushed from the body 
and/or inactivated by the immune system when their host 
is no longer present37, 38. Several studies reported that the 
combined use of phages and antibiotics improved the 
outcome of therapy27. By combined usage of 
bacteriophages and antibiotics, treatment has shown a 
promising: reduction in the amount of bacteria evolving to 
develop antibiotic resistance and increase in the reduction 
of bacterial infection39, 40, 41.  
Phages can be used to combat antibiotic resistance 
through insertion or transfer of susceptible genes back 
into the bacterial genome. This allows bacteria that were 
once antibiotic resistant to regain susceptibility to 
antibiotics. This occurs because the genes that are 
transferred into the bacterium increase the permeability 
of its cell membrane and allow medications to pass 
through it more freely42. In fact, phages have been 
modified to transport clustered regularly interspaced 
short palindromic repeats (CRISPR)-Cas nucleases into 
antibiotic-resistant bacteria. In doing so, researchers are 
going to exploit the specific DNA-cleaving capacity of 
CRISPRs to knock out resistance sequences, rendering 
resistant organisms an antibiotic sensitive43. 
Experiment is being conducted to devise a technique to 
clean hospital surfaces while treating resistant bacteria 
using phages42. It is now also used to improve the shelf-
life of meats, vegetables, fruits and stored plant parts44. 
Researchers have been exploit bacteriophages to 
counteract bioweapons as well as toxins, such as anthrax 
and botulism45. In addition to these, studies have been 
revealed the effectiveness of phages in averting the 
destruction of skin grafts by Peudomona aeruginosa46, 47. A 
few research groups are also engineering phages 
for Methicillin-resistant Staphylococcus aureus treatments 
in variety of forms, including phage-impregnated sutures 
and wound dressings48. Furthermore, current findings on 
bacteriophages are summarized below (Table 1). 
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Table 1: Summary of recent findings on phages related to therapy 
No. Findings Phage(s) name 
used in the study 
Model Ref. 
1 
Demonstrate that six lysins belonging to two different families are 
active against a panel of enteropathogenic C. perfringens strains under 
salinity and acidity conditions relevant to food preparation 
environments and also demonstrate that plant-expressed lysins prevent 
multiplication of C. perfringens on cooked meat matrices far better than 
nisin, the only currently approved bacteriocin food preservative to 
control this pathogen. 
phiSM101, 
vB_CpeS-CP51, 
phiCP26CPE, 
str.4969F, and 
phiCP39-O 
In vitro 
assay 
 
 
49 
2 Isolated a phage that might be used for pathogenic E. coli control. vB_EcoS_HSE2 
In vitro 
assay 
50 
3 
Defines a role for circulating metals as a major factor that is essential 
for the phage-based killing of bacteria in blood. 
HP3, EC1, and CF2 Mice model 51 
4 
Support the idea that phage endolysins are promising candidates for 
developing therapeutics against anthrax infection. 
phage endolysins 
(AP50-31 and 
LysB4) 
In vitro & in 
vivo assays 
52 
5 
Provide novel insights into the role of bacteriophages as potentially 
pathogenic for mammals and their possible implication in the 
development of diseases associated with increased intestinal 
permeability. 
Salmonella phage 
cocktail, 
Pyobacteriophage 
Rat model 53 
6 
The bacteriophages isolated from sewage demonstrated lytic efficacy 
against MDR-bacterial isolates from septic wounds (P. aeruginosa, S. 
aureus, K. pneumoniae and E. coli). 
PA DP4, KP DP1, 
SA DP1, and EC 
DP3 
In vitro 
assay 
54 
7 
Described a preliminary strategy for effective attenuation of Serratia 
growth during ﬁsh spoilage. 
AZT1 up to AZT9 
 
In vitro test 
55 
8 
Suggest opportunities for engineering E. faecalis phages that 
circumvent the problem of bacterial phage resistance. 
E. faecalis V583, 
φVPE25, φ VFW 
 
In vivo assay 
56 
9 
Demonstrated the activity of bacteriophage preparations that are used 
as a part of standard clinical practice in the Republic of Georgia, against 
MDR ESBL-EC isolated from Turkish patients. 
four cocktails 
(Enko-phage, SES-, 
Pyo-, and Intesti-
bacteriophage) 
In vitro spot 
tests 
57 
10 
Highlights the effectiveness of the phage therapy and provides further 
insight into treating infections caused by MDR strains (Acinetobacter 
baumannii) using phage administration. 
vB-GEC_Ab-M-G7 
Rat wound 
model 
58 
 
Enzybiotics, a new development at Rockefeller University, 
generate enzymes from bacteriophage. As an enzybiotic, a 
purified recombinant phage enzyme could be used as 
separate antibacterial agents in their own right59. Direct 
use of phage encoded proteins such as endolysins, 
exopolysaccharidases and holins have shown their ability 
as a potential alternative to antibacterial agents2. Phage 
hyaluronidase can be exploited in suppressing hyaluronan-
mediated tumor growth and progression60. Both phages 
and encoded proteins of phages are used for specific 
identification and detection of bacteria which is reviewed 
in61. Reporter phage assays have been adapted to evaluate 
drug sensitivity in the target bacterium62.   
Bacteriophages are in use for phage display. Phage display 
has a lot of applications in various molecular techniques: in 
new phage development, in purifying antibody or specific 
protein, epitopes mapping during vaccine design, 
specificity determination for enzymes and inhibitors, and 
screening receptors as well as anticancer peptide63, 64.  
They could also be employed as drug delivery system. 
Phages are used in two ways as vehicles for vaccine 
delivery, first directly in bearing vaccine antigens display 
on their surfaces and second in incorporating the gene or 
sequences that synthesized vaccine antigen in to the phage 
genome in DNA vaccine64. Bacteriophages can act as a 
carrier for antibacterial drugs, which are either attached to 
its surface or incorporated into the phage. The obvious 
advantage is that non-speciﬁc antibiotics for example 
chloramphenicol (not frequently used due to its hemolytic 
adverse effects) can be employed owing to a target speciﬁc 
action at the localized place of infection. In contrast to the 
free drug, superior efficiency and enhanced solubility were 
noted65, 66. Bacteriophage targeted delivery of light 
sensitive antibiotics is another approach similar to the 
above principle. This procedure along with subsequent 
irradiation with red light resulted in a much greater 
eradication of Staphylococcus aureus isolates than either 
the phage or light-exposed photosensitizers alone. 
Targeting creates favorable condition to use low 
concentration and light doses so that the adverse effects 
were minimized67.  
Phage coat protein-based vehicles are also being developed 
by anchoring drug-loaded liposomes to capsid proteins 
displaying peptides with binding specificity to a meticulous 
target68. Moreover, the application of phages to 
deliver anticancer drugs to a particular target has been 
illustrated in preliminary in vitro experiments69. 
Bacteriophages having an affinity to specific cell receptors, 
like those over expressed in cancer cells, may be subjugated 
further than drug delivery to let for concurrent target 
detection by displaying diagnostic reporter molecules or by 
detection of bound phage DNA by real-time PCR70, 71.  
Bacteriophages can be employed as specific gene delivery 
vectors. The foreign proteins expressed on the surface of 
phage enable them targeting specific cell types and after 
injection, phage capsid protein save DNA from degradation, 
which is a prerequisite for successful gene therapy42. 
Phage-capsids have been modified to provide the liberation 
of encapsulated RNA-guided endonucleases to specific cell 
types for in situ genome editing72, 73. 
Nureye et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2018; 8(6):278-284 
ISSN: 2250-1177                                                                               [282]                                                                                    CODEN (USA): JDDTAO 
Efforts Made in Ethiopia Regarding 
Bacteriophages  
In Ethiopia, Rhodobacteraceae were revealed to be one of 
the dominant families in the majority of soda lakes 
(Bogoria, Lonar, Zabuye and Kauhako), and the most 
diverse Family in Ethiopian soda lakes74. Van Zyl et al., 
(2016) has described a highly novel Paracoccus infecting 
virus (Shpa) identified from Lake Shala which jointly with 
NgoF6 and vB_PmaS_IMEP1 is one of only three phages 
known to infect Paracoccus species but does not show 
resemblance to this phages75. Generally, there is limited 
study on phage isolation and their therapeutic potential, 
particularly, against multi-drug resistant pathogen in 
Ethiopia. However, bacteriophage having ability of lysing 
MDR Escherichia coli was isolated and demonstrated by 
Getachew and his co-worker76. Moreover, very few review 
articles on phages, which are done by some universities 
from Ethiopia, were existed in scientific journals77, 78. 
Efforts made in Ethiopia are specifically paying attention on 
isolation of bacteriophages from natural sources. 
A New Insight in Ethiopia 
According to Ethiopian Food, Medicine, Healthcare 
Administration and Control Authority (FMHACA), 
antimicrobial misuse together with quick spread of 
resistant microorganisms and non-strong surveillance has 
make worse the situation of antimicrobial resistance (AMR) 
in Ethiopia. Antibiotic resistance is of major community 
health concern in Ethiopia and reached a stage where many 
patients are unable to recover from infections79.  
 Even though extensive studies on AMR in Ethiopia have 
not yet been done, the available reports indicate a tendency 
towards increasing resistance rates among pathogens such 
as Escherichia coli, Staphylococcus aureus, Shigella spp., and 
Salmonella spp. to commonly prescribed antimicrobials 
including ampicillin, amoxicillin, penicillin, tetracycline and 
cotrimoxazole80. Studies done in Addis Ababa revealed that 
serotypes of Salmonella were identified in supermarket 
meat and dairy samples and significant proportion have 
developed resistance for routinely prescribed antibiotics81, 
82.  
Given the harshness of infection due to bacteria, and the 
multifaceted crisis presented by AMR in Ethiopia, it is 
believed that the phage notion should be taken into 
consideration as a precious tool to resolve the existing 
circumstances78. Phage remedy might be an alternative at 
least in certain cases. So, like Western medical 
professionals, health professionals in Ethiopia must have 
increased interest towards researches on phage therapy in 
order to ﬁght against resistant and seriously intimidating 
infections83.  
Non-human applications of phages may signify the widest 
use of these agents, which include use in veterinary, 
agriculture, and food hygiene and food safety78. Their 
beneﬁt could be larger if phage products are accessible in 
developing countries, For instance, given the shortage of 
dependable refrigeration in many lower income countries 
like Ethiopia, meat products are preferably sold within 
twenty four hours of butcher. Thus, any antibacterial agent 
that could augment the shelf life even by one day possibly 
will have signiﬁcant impacts not only on the health of 
community, but also on proﬁtability for meat seller84. 
Studies have verified that Campylobacter is inhabitant in 
the gastrointestinal tracts of up to 75% of poultry in many 
countries85. Thus, bacteriophages could be utilized to 
reduce bacterial loads in animals before they arrive at 
butcher houses84. Agriculture is among the vital economic 
sectors in Ethiopia and bacterial infections that were more 
difficult to control secondary to bactericide resistance are 
the main intimidation to agricultural production of food. 
Bacteriophage could be one of the biological control 
measures that destroy phytopathogens and lessen 
antibiotic and pesticide use thereby reduce the 
development of AMR. 
The country is required in creating proper authoritarian 
guiding principle in advance of completely realizing the 
deployment of phages to improve the health of the 
community. As it is a novel idea, phages are hurdles that 
cause fear and misunderstanding. Therefore, we have to 
elucidate illusions and increase the praise of this most 
recent class of antimicrobial agents. Facilitating and 
organizing workshops as well as training to provide 
information concerning the possible use of bacteriophages, 
deal with safety issues, and get input on how phages could 
be properly applied in Ethiopia78. Additionally, our 
academia can exhaustively extract knowledge and practice 
regarding different aspects of bacteriophage from certain 
international non-governmental organizations of 
professionals which participate in projects, publication and 
education, and organize conference and presentations. For 
example, Phages for Global Health offers laboratory 
training workshops, teaching scientists in third world 
countries about phage biology where the necessity for 
alternatives to antibiotics is felt especially. In fact, the 
second East African Phage Workshop was held at Pwani 
University in Kiliﬁ, Kenya. The trainees were learning how 
to isolate and characterize bacteriophages as antibiotic 
alternatives for use against resistant bacteria83, 84. 
Ethiopia has become a pharmaceutical manufacturing hub 
in Africa86. This occasion may create a favorable ground in 
isolating bacteriophage, manufacturing and 
commercialization of phage products. In support of this, 
product development projects are performed by Phages for 
Global Health in which international multidisciplinary 
teams are assembled that co-develop products from phage 
for speciﬁc applications in third world countries87. Phage 
holds a great potential and it should be exploited in 
Ethiopia, and thus collection of bacteriophages from 
environmental samples that have activity against a variety 
of bacterial hosts should be encouraged. Then after, 
plausible investigations must be done to assemble the 
necessary information with respect to the welfare and 
efficacy of phage therapy and evolutionary outcomes of its 
application78. 
CONCLUSION 
Phages are bacterial viruses which can simply be 
manipulated and have potential uses in research, 
biotechnology, and therapeutics. Increased threat of 
antibiotic resistance makes a great need of new 
antibacterial compounds and search for safe substitutes. 
Related to this context, phage therapy is more and more 
deemed to be a potential alternative. Phages have been 
employed as carriers for drugs as well vaccines, and as 
display systems for many proteins and antibodies. Efforts 
made in Ethiopia about phages are focused on a 
preliminary isolation from natural sources. Given the 
complicated problem presented by antimicrobial resistance 
in Ethiopia, health professionals have to show signs of 
increased interest towards phage therapy.  
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